BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION

BRAZILIAN IBD STUDY GROUP POSITION STATEMENT ON SARS-COV2 VACCINATION

ABSTRACT Mass vaccination offers the best strategy to fight against COVID-19 pandemic, and SARS-CoV2 vaccines are being approved in several countries for emergency use. In Brazil, vaccine approval is expected in the next few days, however potential concerns exist regarding vaccine recommendations for specific populations, such as patients with inflammatory bowel disease (IBD). To address these questions, the Brazilian IBD Study Group (GEDIIB) provides this practical advice with key recommendations about the COVID-19 vaccines in IBD population.

Saved in:
Bibliographic Details
Main Authors: QUEIROZ,Natália Sousa Freitas, TEIXEIRA,Fábio Vieira, FREIRE,Caio Cesar Furtado, MOTTA,Marina Pamponet, VASCONCELLOS,Marcela Almeida Menezes de, CHEBLI,Liliana Andrade, SAAD-HOSSNE,Rogerio
Format: Digital revista
Language:English
Published: Instituto Brasileiro de Estudos e Pesquisas de Gastroenterologia e Outras Especialidades - IBEPEGE. 2021
Online Access:http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032021000100001
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

http://old.scielo.br/scielo.php?script=sci_arttext&pid=S0004-28032021000100001

Similar Items